A case history detailing the rationale behind the discovery of 2-(2,4-difluorophenyl)-1,3-bis(1 H -1,2,4-triazole-1-yl)-2-propyl dihydrogen phosphate, fosfluconazole ( 2 ), a water-soluble prodrug of Diflucan, and the subsequent development of a commercial route is presented. Particular items to note are (i) that this compound was discovered in the Chemical Research and Development Department, hence Chemical Research and Development can play a key role in prodrug discovery, (ii) the strategy behind the selection of phosphate ester promoiety, by phosphorylation of a sterically hindered tertiary alcohol, (iii) the development of the initial route to remove thermally hazardous reagents and to improve processing to allow scale-up, and (iv) the identification and development of the proposed commercial process.
No takes yet. Share an insight, caveat, or question.
Bentley et al. (2001) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: